Clinical trial
Immunogenicity and Safety of 2 Schedules of ALVAC-HIV vCP1452 in Chronically…
NCT00219362 · Objectif Recherche Vaccins SIDA, Other · Completed
Key facts
| NCT number | NCT00219362 |
|---|---|
| Title | Immunogenicity and Safety of 2 Schedules of ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients |
| Official title | A Phase II, Randomized, Placebo-controlled Study to Evaluate the Immunogenicity and the Safety of 2 Schedules of an Homologous Prime-boost With the ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients |
| Acronym | MANON 02 |
| Lead sponsor | Objectif Recherche Vaccins SIDA, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infection |
| Intervention type | Biological |
| Interventions | one injection of vCP1452 at W0, W4, W8 and W20, one injection of vCP1452 at W4, one injection of placebo at W0, W8, W20 or at W4, W20 |
| Enrollment | 65 |
| Start date | Apr 1, 2004 |
| Primary completion | Nov 1, 2005 |
| Completion | Sep 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | Nov 25, 2009 |
| Countries | France, Germany, Spain, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: